Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: Reversal with olanzapine

Behavioural Pharmacology

Volumn 14, Issue 3, 2003, Pages 251-255

  Nel, A ^a   Harvey, Brian H ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Haloperidol; NOS; Olanzapine; Rat; Tardive dyskinesia; VCM

Indexed keywords

HALOPERIDOL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OLANZAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME REPRESSION; MALE; MASTICATION; NEUROMODULATION; NONHUMAN; RAT; TARDIVE DYSKINESIA;

EID: 0038687070     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200305000-00010     Document Type: Article

References (29)

1. Ananth J, Kenan J (1999). Tardive dyskinesia associated with olanzapine monotherapy. J Clin Psychiatry 60:870.
2. Andreassen OA, Jorgenssen HA (2000). Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats, implications for tardive dyskinesia. Prog Neurobiol 61:525-531.
3. Bester A, Harvey BH (2000). Early suppression of striatal cyclic GMP may predetermine the induction and severity of chronic haloperidol-induced vacuous chewing movements. Met Brain Dis 15:273-283.
4. Bredt DS, Schmidt HHHW (1996.) The citrulline assay. In: Feelisch M, Stamler JS (editors): Methods in Nitric Oxide Research. Chichester: John Wiley; p. 249.
5. Cavas M, Navarro JM (2002). Coadministration of L-NOARG and tiapride: effects on catalepsy in male mice. Prog Neuropsychopharmacol Biol Psychiatry 26:69-73.
6. Dawson TM, Sasaki M, Gonzalez-Zulueta M, Dawson VL (1998). Regulation of neuronal nitric oxide synthase and identification of novel nitric oxide signaling pathways. Prog Brain Res 118:3-11.
7. Dawson VL, Dawson TM (1998.) Nitric oxide in neurodegeneration. Prog Brain Res 118:215-229.
8. Egan MF, Hurd Y, Ferguson J, Bachus SE, Hamid EH, Hyde TM (1996). Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology 127:337-345.
9. Esel E, Turan MT, Sofuoglu S, Gönül AS (2000). Improvement of tardive dyskinesia in a bipolar patient with olanzapine. Eur Psychiatry 17:438-439.
10. Fulton B, Goa KL (1997). Olanzapine: A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53:281-298.
11. Gao X-M, Sakai K, Tamminga CA (1998). Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol. Neuropsychopharmacology 19:428-433.
12. Harvey BH, Bester A (2000). Withdrawal-associated changes in peripheral nitrogen oxides and striatal cyclic GMP after chronic haloperidol treatment. Behav Brain Res 111:203-211.
13. Harvey BH, Stein DJ, Emsley RA (1999). The new-generation anti-psychotics: Integrating the neuro-pathology and pharmacology of schizophrenia. S Afr Med J 89:661-672.
14. Herran A, Vazquez-Barquero JL (1999). Tardive dyskinesia associated with olanzapine. Ann Int Med 131:72.
15. Hu J, Lee J-H, El-Fakahany E (1994). Inhibition of neuronal nitric oxide synthase by anti-psychotic drugs. Psychopharmacology 114:161-166.
16. Iwahashi K, Yoneyama H, Ohnishi T, Nakamura K, Miyatake R, Suwaki H, et al. (1996). Haloperidol inhibits neuronal nitric oxide synthase activity by preventing electron transfer. Neuropsychobiology 33:76-79.
17. Llorca P, Chereau I, Bayle F, Lancon C (2002). Tardive dyskinesias and antipsychotics: A review. Eur Psychiatry 17:129-138.
18. Lowry OH, Rosebrough NJ, Farr AL (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
19. Lykouras L, Agelopoulos E, Tzavellas E (2002). Improvement of tardive dyskinesia following switch from neuroleptics to olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 26:815-817.
20. Miller RG (1980.) Simultaneous Statistical Inference. 2nd ed. New York: Springer-Verlag.
21. Naidu PS, Kulkarni SK (2001a). Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCM's): Possible involvement of calcium and nitric oxide. Behav Pharmacol 12:209-216.
22. Naidu PS, Kulkarni SK (2001b). Effect of 5HT1A and 5HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Eur J Pharmacol 428:81-86.
23. Raymond JR, Mukhin YV, Gelasco A, Turner J, Collinsworth G, Gettys TW, et al. (2001). Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther 92:179-212.
24. Richelson E, Souder T (2000). Binding of antipsychotic drugs to human brain receptors: Focus on newer generation compounds. Life Sci 68:29-39.
25. Simpson GM (2000). The treatment of tardive dyskinesia and tardive dystonia. J Clin Psychiatry 61:39-44.
26. Tarazi FI, Zhang K, Baldessarini RJ (2002). Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. Nitric Oxide 7:297-300.
27. Turrone P, Remington G, Nobrega JN (2002). The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D2 receptor occupancy? Neurosci Biobehav Rev 26:361-380.
28. West AR, Galloway MP, Grace AA (2002). Regulation of striatal dopamine neurotransmission by nitric oxide: effector pathways and signaling mechanisms. Synapse 44:227-245.
29. Wink DA, Vodovotz Y, Grisham MB, DeGraff W, Cook JC, Pacelli R, et al. (1999). Antioxidant effects of nitric oxide. Methods Enzymol 301:413-424.